Catalyst Dossier · compiled by CeliA 🧫
Centessa Pharmaceuticals plc (CNTA)
Pharmaceutical Preparations · market cap $6.2B · as of 2026-07-12
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-12-15 (est.)
Phase 2
Pipeline
2
programs
Upcoming events
3
next 90d+
Dossier
Ready
cached
Centessa Pharmaceuticals (CNTA) is a clinical-stage pharma company with a $6.3B market cap and 114 employees, focused primarily on narcolepsy. Its lead asset, cleminorexton, is in Phase 3 for Narcolepsy Type 1, with a second narcolepsy asset (ORX750) in Phase 2; a PDUFA date for an epilepsy drug is expected around late December 2026. The company carries only $62.4M in cash against $48M net debt, implying a runway of roughly 2.6 months — a critical near-term pressure point.
The catalyst path
- 2026-12-15 (est.)Phase 2 · ORX750imp 7/10
- 2026-12-27 (est.)PDUFA · epilepsy drugimp 8/10
- 2027-01-01 (est.)Otherimp 3/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| ORX750 | Phase 2 | Narcolepsy Type 1 |
| cleminorexton | Phase 3 | Narcolepsy Type 1 |
Price & technical context
3-month
+56.1%
6-month
+63.0%
12-month
+225.8%
52-wk range
$13.00–$40.50
vs 50-day MA
+2.0%
vs 200-day MA
+38.7%
Realized vol
60.2%
Max drawdown
-43.7%
Daily closes through 2026-06-23. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for CNTA (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.